Logo
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Ελληνικά 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Σύνδεση
Προβολή τεκμηρίου 
  •   Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Προβολή τεκμηρίου
  •   Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Προβολή τεκμηρίου
JavaScript is disabled for your browser. Some features of this site may not work without it.
Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας
Όλο το DSpace
  • Κοινότητες & Συλλογές
  • Ανά ημερομηνία δημοσίευσης
  • Συγγραφείς
  • Τίτλοι
  • Λέξεις κλειδιά

Prostate cancer: ESMO consensus conference guidelines 2012

Thumbnail
Συγγραφέας
Horwich, A.; Hugosson, J.; de reijke, T.; Wiegel, T.; Fizazi, K.; Kataja, V.; Parker, C.; Bellmunt, J.; Berthold, D.; Bill-axelson, A.; Carlsson, S.; Daugaard, G.; De meerleer, G.; De reijke, T.; Dearnaley, D.; Fonteyne, V.; Gillessen, S.; Heinrich, D.; Kwiatkowski, M.; Nilsson, S.; Padhani, A.; Papandreou, C.; Roobol, M.; Sella, A.; Valdagni, R.; Van der kwast, T.; Verhagen, P.
Ημερομηνία
2013
DOI
10.1093/annonc/mds624
Λέξη-κλειδί
Consensus
ESMO
Prostate cancer
abiraterone
abiraterone acetate
antiandrogen
bicalutamide
cabazitaxel
clodronic acid
denosumab
docetaxel
enzalutamide
gonadorelin agonist
gonadorelin antagonist
gonadorelin derivative
pamidronic acid
placebo
prednisone
prostate specific antigen
radioisotope
radium 223
sipuleucel T
unclassified drug
zoledronic acid
age
androgen deprivation therapy
article
bone metastasis
brachytherapy
cancer diagnosis
cancer hormone therapy
cancer localization
cancer screening
cancer staging
castration resistant prostate cancer
clinical effectiveness
comorbidity
digital rectal examination
drug efficacy
drug treatment failure
European Society for Medical Oncology
external beam radiotherapy
family history
human
hypocalcemia
image guided radiotherapy
intensity modulated radiation therapy
jaw osteonecrosis
lymph node dissection
medical society
metastatic hormone naive prostate cancer
nomogram
pelvis lymph node
practice guideline
priority journal
prostate biopsy
prostatectomy
radiation dose
Switzerland
symptom
transrectal ultrasonography
Antineoplastic Agents, Hormonal
Humans
Lymph Nodes
Male
Prostate-Specific Antigen
Prostatic Neoplasms
Εμφάνιση Μεταδεδομένων
Επιτομή
The first ESMO Consensus Conference on prostate cancer was held in Zurich, Switzerland, on 17-19 November 2011, with the participation of a multidisciplinary panel of leading professionals including experts in methodological aspects. Before the conference, the expert panel prepared clinically relevant questions about prostate cancer in four areas for discussion as follows: diagnosis and staging, management of early localized disease, management of advanced localized disease and systemic disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update. © The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
URI
http://hdl.handle.net/11615/28504
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19735]

Related items

Showing items related by title, author, creator and subject.

  • Thumbnail

    Dietary factors and supplements influencing prostate specific-antigen (PSA) concentrations in men with prostate cancer and increased cancer risk: An evidence analysis review based on randomized controlled trials 

    Grammatikopoulou M.G., Gkiouras K., Papageorgiou S.Τ., Myrogiannis I., Mykoniatis I., Papamitsou T., Bogdanos D.P., Goulis D.G. (2020)
    The quest for dietary patterns and supplements efficient in down-regulating prostate-specific antigen (PSA) concentrations among men with prostate cancer (PCa) or increased PCa risk has been long. Several antioxidants, ...
  • Thumbnail

    Targeting neuroendocrine prostate cancer: Molecular and clinical perspectives 

    Vlachostergios, P. J.; Papandreou, C. N. (2015)
    Neuroendocrine prostate carcinoma, either co-present with the local adenocarcinoma disease or as a result of transdifferentiation later in time, was described as one major process of emerging resistance to androgen deprivation ...
  • Thumbnail

    Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival 

    Vlachostergios P.J., Karathanasis A., Tzortzis V. (2022)
    Background: Advanced prostate cancer (PC) may accumulate genomic alterations that hallmark lineage plasticity and transdifferentiation to a neuroendocrine (NE) phenotype. Fibroblast activation protein (FAP) is a key player ...
htmlmap 

 

Πλοήγηση

Όλο το DSpaceΚοινότητες & ΣυλλογέςΑνά ημερομηνία δημοσίευσηςΣυγγραφείςΤίτλοιΛέξεις κλειδιάΑυτή η συλλογήΑνά ημερομηνία δημοσίευσηςΣυγγραφείςΤίτλοιΛέξεις κλειδιά

Ο λογαριασμός μου

ΣύνδεσηΕγγραφή (MyDSpace)
Πληροφορίες-Επικοινωνία
ΑπόθεσηΣχετικά μεΒοήθειαΕπικοινωνήστε μαζί μας
Επιλογή ΓλώσσαςΌλο το DSpace
EnglishΕλληνικά
htmlmap